title: [The survival of patients with radically non-resectable pancreatic cancer].
abstract: BACKGROUND
  Pancreatic cancer (PDAC) is one of the most aggressive malignancies. Its poor prognosis is due to a combination of various factors, mainly aggressive biology of the tumour, non-specific symptoms in early stages, their underestimation, prolonged time to diagnosis and late onset of treatment. The majority of patients are diagnosed in an advanced stage of the disease. Median survival of these patients ranges from 211 months. The most common consequences of locally advanced disease that require intervention include obstruction of the duodenum and biliary obstruction. The purpose of our study was to analyze the survival of patients with radically inoperable PDAC undergoing palliative surgery or exploration with biopsy, and to evaluate the influence of patient and tumour factors and treatment modalities on survival.
  
  
  METHODS
  In our retrospective study we included all patients with radically inoperable PDAC undergoing a non-radical surgical intervention between 01 January 2006 and 31 December 2014. Patient age, histopathological findings, surgical and oncological treatment and survival were included in the analysis. The results were statistically processed and evaluated using IBM SPSS Statistics software version 22 (USA).
  
  
  RESULTS
  184 patients with radically inoperable PDAC, 105 males and 79 females, were included in our study. Mean age of the patients was 64 years and most patients presented with stage IV of the disease. Mean survival time was 7.04 months and median 4.7 months.
  
  
  CONCLUSIONS
  We determined a statistically significant influence of the following factors on patient survival: sex, stage, presence of distant metastases at the time of surgery and oncological treatment administration. Mean and median survival of patients with radically inoperable tumours matches global statistics.
  
  
  BACKGROUND
  pancreatic cancer - radically non-resectable - palliative surgery - survival.
authors.forename: L
authors.initials: L
authors.lastname: Bébarová
authors.forename: P
authors.initials: P
authors.lastname: Skalický
authors.forename: D
authors.initials: D
authors.lastname: Klos
authors.forename: R
authors.initials: R
authors.lastname: Havlík
authors.forename: Č
authors.initials: Č
authors.lastname: Neoral
authors.forename: J
authors.initials: J
authors.lastname: Zapletalová
authors.forename: M
authors.initials: M
authors.lastname: Loveček
mesh_terms: D000368:Aged; D001706:Biopsy; D021441:Carcinoma, Pancreatic Ductal / Q000401:mortality* / Q000628:therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000401:mortality* / Q000628:therapy; D012189:Retrospective Studies; D015996:Survival Rate